One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 850,000 shares of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK | TAK Price Prediction) on Tuesday, as the share price of this fund traded was up 7% in the day’s session. Its share price is still negative over the past year.
[in-text-ad]
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 846,189 shares of Takeda. At Tuesday’s closing price, this would have valued this sale at roughly $11.7 million. This is only a small fraction of the total holdings. This fund is down 32% over the past 52 weeks.
[nativounit]
Here is a quick look at all the trades that took place across all ARK ETFs:
| Fund | Direction | Ticker | Name | Shares |
|---|---|---|---|---|
| ARKF | Buy | DSYSJ | DISCOVERY | 55,621 |
| ARKG | Buy | SGFY | SIGNIFY HEALTH | 160,234 |
| ARKG | Sell | TAK | TAKEDA PHARMACEUTICAL | 846,189 |
| ARKK | Buy | SGFY | SIGNIFY HEALTH | 313,766 |
| ARKK | Buy | TDOC | TELADOC HEALTH | 63,567 |
| ARKK | Sell | EDIT | EDITAS MEDICINE | 138,796 |
| ARKQ | Buy | BLDE | BLADE AIR MOBILITY | 11,926 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
[recirclink id=1008967][wallst_email_signup]